1. Home
  2. PLRX vs PCRX Comparison

PLRX vs PCRX Comparison

Compare PLRX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

N/A

Current Price

$1.13

Market Cap

73.7M

Sector

Health Care

ML Signal

N/A

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$24.68

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLRX
PCRX
Founded
2015
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.7M
1.1B
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
PLRX
PCRX
Price
$1.13
$24.68
Analyst Decision
Hold
Strong Buy
Analyst Count
4
4
Target Price
$2.67
$30.25
AVG Volume (30 Days)
377.1K
432.4K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
29.97
107.44
EPS
N/A
0.19
Revenue
N/A
$541,533,000.00
Revenue This Year
N/A
$6.78
Revenue Next Year
N/A
$8.54
P/E Ratio
N/A
$128.84
Revenue Growth
N/A
26.04
52 Week Low
$1.02
$18.80
52 Week High
$1.95
$27.66

Technical Indicators

Market Signals
Indicator
PLRX
PCRX
Relative Strength Index (RSI) 49.73 43.00
Support Level $1.11 $21.97
Resistance Level $1.21 $27.05
Average True Range (ATR) 0.05 0.72
MACD -0.00 -0.18
Stochastic Oscillator 47.83 22.70

Price Performance

Historical Comparison
PLRX
PCRX

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: